On global landscape, companies must be aware of crucial safety information regarding their portfolio in order to evaluate product benefit/risk profiles. Pharmacovigilance is important at every stage of a product’s lifecycle, from preclinical studies through post-approval stages including the first few years after launch, when knowledge of the safety profile expands based on exposure to a much wider range of patients than is possible during clinical trials.